Introduction Perampanel is a selective, non-competitive AMPA receptor antagonist with a broad-spectrum activity. The aim of this study was to evaluate the efficacy and tolerability of Perampanel in an unselected group of patients with epilepsy treated at a single centre.
Methods Patients prescribed Perampanel in Morriston Hospital were included in the study. We recorded epilepsy type and duration, and side effects of treatment. The efficacy was measured by the frequency of seizures at various time points after commencing Perampanel
Results 39 patients were included, 53.8% (21/39) male and 46.2% (18/39) females, mean age was thirty-nine. 71.8% (28/39) had focal epilepsy and 82.1% (32/39) were on 2 or more anti-epileptic drugs (AEDs). 30.7% (12/39) of patients reported more than 50% improvement in the frequency of seizures after commencing Perampanel. 38.4% (15/39) reported no change, 5% (2/39) of patients reported worsening of seizures. The most commonly reported side effects were aggression 25.6% (10/39), low mood 20.5% (8/39) and dizziness 15.3% (6/39).
Conclusion Perampanel showed mixed results in relation to seizure frequency reductions and the most commonly reported side effects were low mood and aggression. We plan to extend the study to include patients from other south wales centres and calculate overall retention rates.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.